Cost Effectiveness of Current Approaches to the Control of Retinopathy in Type I Diabetics

Keyphrases

• Cost-effectiveness 100%
• Retinopathy 100%
• Type 1 Diabetic 100%
• Macular Edema 66%
• Diabetic Retinopathy 66%
• Population-based Study 33%
• Epidemiology 33%
• Randomized Controlled Trial 33%
• Diabetic 33%
• Public Health 33%
• Clinical Trials 33%
• Causes of Blindness 33%
• Treatment Recommendations 33%
• Acuity 33%
• Treatment Efficacy 33%
• Vision Loss 33%
• Blindness 33%
• Working Population 33%
• Early Treatment Diabetic Retinopathy Study 33%
• Diabetic Macular Edema 33%
• Medicare Reimbursement 33%
• Laser Therapy 33%
• Proliferative Diabetic Retinopathy 33%
• Panretinal Photocoagulation 33%
• Economic Effect 33%
• Model Support 33%
• Proliferative Vitreoretinopathy 33%
• American Academy of Ophthalmology 33%
• Diabetic Eye Disease 33%
• Reimbursement Data 33%
• Computer Simulation Model 33%
• Medical Effects 33%
• Medically Uninsured 33%
• Social Security Disability 33%
• Health Committees 33%
• Eye Care 33%
• Diabetic Retinopathy Study 33%

Medicine and Dentistry

• Diabetes Mellitus 100%
• Health Care Cost 100%
• Retinopathy 100%
• Diabetic Retinopathy 80%
• Macular Edema 40%
• Public Health 20%
• Cohort Effect 20%
• Randomized Controlled Trial 20%
• Eye Disease 20%
• Clinical Trial 20%
• Laser Coagulation 20%
• Visual Impairment 20%
• Ophthalmology 20%
• Medicare 20%
• Eye Care 20%
• Proliferative Diabetic Retinopathy 20%
• Proliferative Retinopathy 20%
• Low Level Laser Therapy 20%